Myeloma Novel Drug Discovery Ver 1.2

Recruiting

• Conditions: Multiple Myeloma
• Interventions: Other: Observational study - sample collection only.

• Registration Number: NCT05968417
• Lead Sponsor: Institute of Cancer Research, United Kingdom

Brief Summary

Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-22
• Study First Submitted: 2023-07-21
• Study First Submitted QC: 2023-07-21
• Status Verified: 2023-08
• Study First Posted: 2023-08-01
• Last Update Submitted: 2023-08-01
• Last Update Posted: 2023-08-03
• Primary Completion: 2033-02-28
• Study Completion: 2035-02-28

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

1. Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
2. Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment
3. Participants aged 18 years of age or above
4. Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling

Exclusion Criteria

1. Participants unable to provide consent
2. Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Participants with a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder	Observational study - sample collection only.	Participants who are undergoing peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment will be approached to collect additional samples for research.

Primary Outcome Measures

Name	Time	Method
Cell viability	12 months	Myeloma cell viability when incubated with standard of care and novel compounds.

Trial Locations

Locations (1)

The Royal Marsden NHS Foundation Trust; 🇬🇧 London Borough of Sutton, United Kingdom